Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Garber ST, et al. Among authors: weathers sp. Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1. Neuro Oncol. 2016. PMID: 27370400 Free PMC article.
Tumor Vaccines for Malignant Gliomas.
Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB. Srinivasan VM, et al. Among authors: weathers sp. Neurotherapeutics. 2017 Apr;14(2):345-357. doi: 10.1007/s13311-017-0522-2. Neurotherapeutics. 2017. PMID: 28389997 Free PMC article. Review.
Pre-surgical connectome features predict IDH status in diffuse gliomas.
Kesler SR, Harrison RA, Petersen ML, Rao V, Dyson H, Alfaro-Munoz K, Weathers SP, de Groot J. Kesler SR, et al. Among authors: weathers sp. Oncotarget. 2019 Nov 5;10(60):6484-6493. doi: 10.18632/oncotarget.27301. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741712 Free PMC article.
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. de Groot J, et al. Among authors: weathers sp. Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185. Neuro Oncol. 2020. PMID: 31755915 Free PMC article.
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Weathers SP, et al. Clin Cancer Res. 2020 Jul 15;26(14):3565-3577. doi: 10.1158/1078-0432.CCR-20-0176. Epub 2020 Apr 16. Clin Cancer Res. 2020. PMID: 32299815 Free PMC article. Clinical Trial.
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien B, Weathers SP, Matsouka CK, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. Groot J, et al. Among authors: weathers sp. CNS Oncol. 2022 Jun 1;11(2):CNS87. doi: 10.2217/cns-2022-0005. Epub 2022 May 16. CNS Oncol. 2022. PMID: 35575067 Free PMC article. Clinical Trial.
Resistance to antiangiogenic therapy.
Weathers SP, de Groot J. Weathers SP, et al. Curr Neurol Neurosci Rep. 2014 May;14(5):443. doi: 10.1007/s11910-014-0443-y. Curr Neurol Neurosci Rep. 2014. PMID: 24652451 Review.
52 results